Antimicrobials
Daptomycin

Daptomycin

Restricted

Low
N/A
$$ ($26-$100/day)

Spectrum of Activity

General Information

  • CPK at least once weekly
  • Myopathy, muscle weakness

  • Rhabdomyolysis

  • HMG-CoA Reductase Inhibitors (Statins): May enhance the adverse/toxic effect of DAPTOmycin
  • Specifically, the risk of skeletal muscle toxicity may be increased
  • Management: 
    • Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin
    • If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended

Cubicin, Cubicin-RF

  • Distribution: 0.1 L/kg

  • Protein binding: 90% to 93%

  • Metabolism: Minor

  • Half-life elimination: 8-9 hrs

  • Excretion: Urine (78%; primarily as unchanged drug); feces (5.7%)

  • Clearance: 8.3-9 mL/hr/kg

Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection